Lifeloc Technologies reported Q3 2026 net revenue of $2.522 million, a 12% increase year-over-year, and a narrowed net loss of $85 thousand. The company highlighted margin improvements from price increases and continued heavy R&D investment in its SpinDetect drug analyzer platform, which is entering beta testing.
Lifeloc Technologies reported a net loss of $84,931 for the third quarter of 2026, an improvement from the $263,439 loss in the prior year period, driven by a 12% increase in total revenues. For the nine months ended September 30, 2026, the company reduced its operating loss to $281,649 compared to $893,139 in 2025, while securing a $500,000 related-party term loan to bolster cash reserves.
Lifeloc Technologies announced its participation in the Lytham Partners Fall 2026 Investor Conference, featuring a virtual webcast presentation and one-on-one investor meetings. Management intends to provide a business update on its breath alcohol testing operations and the development status of its SpinDetect Analyzer for rapid drug testing.